LONDON--GlaxoSmithKline PLC (GSK.LN), a research-based
pharmaceutical and healthcare company, said Friday that it has
extended its tender offer to acquire all of the outstanding shares
of Human Genome Sciences (HGSI) for 13.00 dollars per share in cash
to 2200 GMT on June 29.
MAIN FACTS:
-The tender offer was previously scheduled to expire at 0500
GMT, at the end of the day on June 8.
-GSK's offer represents a premium of 81% to HGS's closing share
price of $7.17 on April 18, the last trading day before HGS
publicly disclosed GSK's private offer.
-As of 0500 GMT at the end of the day on June 8, 474,029 shares
including 24,856 shares subject to guarantees of delivery had been
tendered and not withdrawn, pursuant to the offer.
-GlaxoSmithKline shares at 1238 GMT up 14 pence, or 1.0%, at
GBP14.45, valuing the company at GBP71.73 billion.
-Write to Razak Musah Baba at razak.baba@dowjones.com